SHINVA(SH:600587) Sou Hu Cai Jing·2025-09-01 11:32Financial Performance - For the first half of 2025, the company's operating revenue was approximately 4.79 billion, a decrease from 5.19 billion in the same period last year, representing a decline of about 7.6% [1] - The total profit for the same period was approximately 454 million, down from 567 million year-on-year, indicating a decrease of about 20% [1] - The net profit attributable to shareholders was approximately 386 million, compared to 484 million in the previous year, reflecting a decline of about 20.2% [1] - The net profit after deducting non-recurring gains and losses was approximately 333 million, down from 474 million, a decrease of about 29.6% [1] - The net cash flow from operating activities was approximately 243 million, showing a significant increase of 76.9% compared to 137 million in the previous year [1] Asset and Liability Changes - As of the end of the first half of 2025, the company's net assets attributable to shareholders were approximately 7.86 billion, an increase from 7.60 billion at the end of the previous year [1] - The company's inventory decreased by 7.78% compared to the end of the previous year, while fixed assets increased by 5.34% [39] - Contract liabilities decreased by 16.32%, while other payables increased by 33.69% [42] Shareholder Structure - The largest shareholder is Shandong Yiyang Health Industry Development Group Co., Ltd., holding approximately 28.91% of the shares [54] - Other notable shareholders include Huabao Zhongzheng Medical ETF and Hong Kong Central Clearing Limited, which have increased their holdings [54] Valuation Metrics - As of August 29, the company's price-to-earnings (P/E) ratio was approximately 16.65, the price-to-book (P/B) ratio was about 1.26, and the price-to-sales (P/S) ratio was around 1.03 [1]